首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1702365

全球基因檢測市場 - 2025-2033

Global Genetic Testing Market - 2025-2033

出版日期: 2025年04月10日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年全球基因檢測市場規模達147.2億美元，預計到2033年將達到542.1億美元，在2025-2033年的預測期內複合年成長率為15.4%。

全球基因檢測市場是指使用分析 DNA、RNA 或蛋白質的診斷測試來識別遺傳狀況、遺傳疾病和未來健康狀況的風險。該市場包括各種類型的基因測試，例如攜帶者測試、診斷測試、預測測試、產前測試和藥物基因組學。這些測試有助於診斷疾病、了解遺傳傾向並制定個人化治療策略。

基因檢測可以實現個人化治療策略，根據個人基因特徵客製化醫療保健。它有助於早期診斷，透過確定最佳治療方案和避免不良藥物反應來改善患者的治療效果。

市場動態：

駕駛員和約束裝置

遺傳性疾病和慢性病盛行率不斷上升

遺傳疾病和慢性病的日益普及預計將極大地推動基因檢測市場的成長。隨著囊性纖維化、鐮狀細胞性貧血和亨廷頓氏症等遺傳疾病的發生率不斷上升，對基因檢測的需求也在增加。例如，根據囊性纖維化基金會的數據，每年約有 1,000 例新的 CF 病例被診斷出來。每年數量的增加都增加了對先進檢測程序的需求，以便在早期診斷病情。

透過基因檢測進行早期發現可以幫助醫療保健提供者提供個人化的治療方案，從而有可能改善治療效果並從長遠來看降低醫療保健成本。此外，癌症、糖尿病和心血管疾病等慢性疾病的發生率不斷上升，進一步增加了基因檢測的需求。

許多患有慢性疾病的人都被要求進行基因檢測或對此感興趣，以便準確診斷疾病。例如，根據芝加哥大學 NORC 2022 年的調查，17% 的美國人實際上已經接受過基因檢測，52% 的人表示對此類檢測感興趣。因此，預計上述因素將推動市場成長。

基因檢測和定序技術成本高昂

基因檢測和定序技術的高成本預計將成為基因檢測市場成長的重大障礙。儘管基因檢測取得了進步，但與次世代定序 (NGS) 等定序技術相關的費用仍然相對較高，使得很大一部分人無法負擔這些檢測的費用。

高昂的成本可能會限制人們獲得基因檢測的機會，特別是對於已開發市場和新興市場中服務不足的人。例如，許多人可能無法負擔疾病風險評估、產前篩檢或個人化醫療的測試，這可能會阻礙早期診斷或個人化治療計劃，而這些計劃可以顯著改善健康結果。

因此，基因檢測和定序技術的高成本可能會限制可及性和減少需求，從而阻礙市場的成長。因此，上述因素可能會限制全球基因檢測市場的潛在成長。

影響因素
- 驅動程式
  - 遺傳性疾病和慢性病盛行率不斷上升
  - 下一代定序 (NGS) 和 PCR 技術的進展
- 限制
  - 基因檢測和定序技術成本高昂
  - 關於基因數據的倫理和隱私問題
- 機會
  - 具有尚未開發的成長潛力的新興市場
- 影響分析

第4章：戰略洞察與產業展望

市場領導者和先驅者
- 新興先鋒和傑出參與者
- 擁有最大銷售品牌的既定領導者
- 擁有成熟產品的市場領導者
CXO 觀點
最新進展與突破
案例研究/正在進行的研究
監管和報銷情況
- 北美洲
- 歐洲
- 亞太地區
- 南美洲
- 中東和非洲
波特五力分析
供應鏈分析
專利分析
SWOT分析
未滿足的需求和差距
市場進入和擴張的推薦策略
情境分析：最佳情況、基本情況和最壞情況預測
定價分析和價格動態
關鍵意見領袖

第5章：基因檢測市場（依產品類型）

耗材
裝置
軟體

第6章：基因檢測市場（依技術）

下一代定序（NGS）
聚合酶鍊式反應（PCR）
螢光原位雜合技術（FISH測試）
其他

第7章：基因檢測市場（依檢測類型）

攜帶者檢測
產前和新生兒檢測
植入前檢查
預測性和症狀前檢測
法醫檢測
診斷測試
其他

第 8 章：基因檢測市場（按應用）

癌症診斷
遺傳疾病診斷
心血管疾病診斷
其他

第9章：基因檢測市場，依區域市場分析與成長機會

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
南美洲
- 巴西
- 阿根廷
- 南美洲其他地區
亞太
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲

第10章：競爭格局與市場定位

競爭概況和主要市場參與者
市佔率分析與定位矩陣
策略夥伴關係、併購
產品組合和創新的關鍵發展
公司基準化分析

第 11 章：公司簡介

雅培實驗室
公司概況
產品組合
- 產品描述
- 產品關鍵績效指標 (KPI)
- 歷史和預測產品銷售
- 產品銷售量
財務概覽
- 公司收入
- 地區收入佔有率
- 收入預測
關鍵進展
- 併購
- 關鍵產品開發活動
- 監管部門批准等
SWOT分析

BioRad實驗室公司
Illumina公司
Myriad Genetics公司
丹納赫公司
Quest Diagnostics公司
醫學基因組
LabCorp
3billion公司
藍圖遺傳學

第 12 章：假設與研究方法

資料收集方法
數據三角測量
預測技術
數據驗證和確認

第 13 章：附錄

簡介目錄

Product Code: BT226

The global genetic testing market reached US$ 14.72 billion in 2024 and is expected to reach US$ 54.21 billion by 2033, growing at a CAGR of 15.4 % during the forecast period of 2025-2033.

The global genetic testing market refers to the use of diagnostic tests that analyze DNA, RNA, or proteins to identify genetic conditions, hereditary diseases, and the risk of future health conditions. This market includes various types of genetic tests, such as carrier testing, diagnostic testing, predictive testing, prenatal testing, and pharmacogenomics. These tests help in diagnosing diseases, understanding genetic predispositions, and enabling personalized treatment strategies.

Genetic testing allows for personalized treatment strategies, tailoring healthcare to individual genetic profiles. It aids in early diagnosis, improving patient outcomes by identifying the best treatment options and avoiding adverse drug reactions.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Genetic Disorders and Chronic Diseases

The increasing prevalence of genetic disorders and chronic diseases is expected to significantly drive the growth of the genetic testing market. As the incidence of genetic conditions like cystic fibrosis, sickle cell anemia, and Huntington's disease continues to rise, the demand for genetic testing is also growing. For instance, according to the Cystic Fibrosis Foundation, approximately 1,000 new cases of CF are diagnosed each year. This increase in the number every year increases the demand for advanced testing procedures to diagnose the condition at an early stage.

Early detection through genetic testing can help healthcare providers offer personalized treatment plans, potentially improving outcomes and reducing healthcare costs in the long run. In addition, the rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions is increasing the need for genetic testing even more.

A large number of individuals suffering from chronic diseases are prescribed or are showing interest in genetic testing to diagnose the disease accurately. For instance, according to the NORC at the University of Chicago in 2022, it is stated that 17 percent of Americans have actually undergone genetic testing, and 52 percent report interest in such a test. Thus, the above factors are expected to drive the market growth.

High Cost of Genetic Tests and Sequencing Technologies

The high cost of genetic tests and sequencing technologies is expected to be a significant barrier to the growth of the genetic testing market. Despite advancements in genetic testing, the expenses associated with sequencing technologies, such as next-generation sequencing (NGS), remain relatively high, making these tests unaffordable for a large portion of the population.

This high cost can limit access to genetic testing, particularly for underserved populations in both developed and emerging markets. For example, many individuals may be unable to afford tests for disease risk assessment, prenatal screening, or personalized medicine, which could prevent early diagnosis or personalized treatment plans that could significantly improve health outcomes.

As a result, the high cost of genetic tests and sequencing technologies is likely to hinder the market's growth by limiting accessibility and reducing demand. Thus, the above factors could be limiting the global genetic testing market's potential growth.

Segment Analysis

The global genetic testing market is segmented based on product type, technology, testing type, application, and region.

Technology:

The next-generation sequencing (NGS) segment in technology is expected to dominate the global genetic testing market with the highest market share

Next-Generation Sequencing (NGS) is a transformative technology in the genetic testing market, enabling the rapid and cost-effective sequencing of DNA and RNA. It is widely used in various applications, including clinical diagnostics, oncology, precision medicine, biomarker discovery, and agriculture. The global NGS market is experiencing strong growth, driven by advancements in sequencing technology, decreasing costs, and increasing demand for personalized medicine and genetic research.

For instance, in February 2025, Devyser launched Devyser Thalassemia v2, a next-generation sequencing (NGS) solution aimed at improving the accuracy and efficiency of genetic testing for alpha and beta thalassemia. This new version enhances the detection of structural variants and copy number variations (CNVs), providing broader and more precise screening capabilities. This innovation aligns with the growing demand for high-accuracy genetic diagnostics, particularly in the expanding NGS segment in the market.

Geographical Analysis

North America is expected to hold a significant position in the global genetic testing market, with the highest market share

North America is expected to dominate the genetic testing market due to various significant factors. The growing prevalence of chronic diseases, and genetic disorders in North America fuels the demand for genetic testing. As more individuals are diagnosed with conditions such as diabetes, cancer, and hereditary diseases, there is a growing demand for genetic testing to help in early diagnosis, risk assessment, and personalized treatment planning.

For instance, according to the report by the American Cancer Society in 2025, it is stated that approximately 1 in 8 women in the United States are diagnosed with breast cancer. Being one of the common cancers among women, the need for genetic testing is expected to increase, which is expected to drive the genetic testing market. Genetic testing detects inherited genetic mutations for various cancers.

Companies in the region are mainly focusing on developing advanced solutions for the diagnosis of genetic diseases to help in identifying the mutations in the genes and help in developing personalized medicine. For instance, in March 2024, Nucleus Genomics, a next-generation genetic testing and analysis company, launched its DNA analysis product aimed at making the benefits of personalized medicine accessible to everyone. This product is designed to empower individuals with the knowledge of their genetic makeup, helping them make informed decisions about their health.

Moreover, North America has one of the highest adoption rates of personalized medicine, where genetic tests play a crucial role in tailoring treatments to individual patients based on their genetic makeup. Thus, various factors are contributing to the region's dominant position in the global genetic testing market.

Competitive Landscape

The major global players in the genetic testing market include Abbott Laboratories, Bio-Rad Laboratories Inc., Illumina Inc., Myriad Genetics Inc., Danaher Corporation, Quest Diagnostics Incorporated, MedGenome, LabCorp, 3billion, Inc., and Blueprint Genetics, among others.

Key Developments

In August 2024, Nonacus launched the GALEAS Tumor test, a comprehensive genomic profiling (CGP) solution designed to analyze tumor genetics using next-generation sequencing (NGS). This test integrates bioinformatics and analysis software, making it easier for clinicians to detect genetic mutations linked to various cancers, including rare and complex ones like brain tumors.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global genetic testing market report delivers a detailed analysis with 70 key tables, more than 68 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Market Introduction and Scope

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. Executive Insights and Key Takeaways

2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Technology
2.5. Snippet by Testing Type
2.6. Snippet by Application
2.7. Snippet by Region

3. Dynamics

3.1. Impacting Factors
- 3.1.1. Drivers
  - 3.1.1.1. Increasing Prevalence of Genetic Disorders and Chronic Diseases
  - 3.1.1.2. Advances In Next-Generation Sequencing (NGS) and PCR Technologies
- 3.1.2. Restraints
  - 3.1.2.1. High Cost of Genetic Tests and Sequencing Technologies
  - 3.1.2.2. Ethical and Privacy Concerns Regarding Genetic Data
- 3.1.3. Opportunity
  - 3.1.3.1. Emerging Markets with Untapped Growth Potential
- 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

4.1. Market Leaders and Pioneers
- 4.1.1. Emerging Pioneers and Prominent Players
- 4.1.2. Established leaders with the largest-selling Brand
- 4.1.3. Market leaders with established Product
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Case Studies/Ongoing Research
4.5. Regulatory and Reimbursement Landscape
- 4.5.1. North America
- 4.5.2. Europe
- 4.5.3. Asia Pacific
- 4.5.4. South America
- 4.5.5. Middle East & Africa
4.6. Porter's Five Forces Analysis
4.7. Supply Chain Analysis
4.8. Patent Analysis
4.9. SWOT Analysis
4.10. Unmet Needs and Gaps
4.11. Recommended Strategies for Market Entry and Expansion
4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.13. Pricing Analysis and Price Dynamics
4.14. Key Opinion Leaders

5. Genetic Testing Market, By Product Type

5.1. Introduction
- 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 5.1.2. Market Attractiveness Index By Product Type
5.2. Consumables*
- 5.2.1. Introduction
- 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Equipment
5.4. Software

6. Genetic Testing Market, By Technology

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 6.1.2. Market Attractiveness Index By Technology
6.2. Next-Generation Sequencing (NGS)*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Polymerase Chain Reaction (PCR)
6.4. Fluorescence in Situ Hybridization (FISH Test)
6.5. Others

7. Genetic Testing Market, By Testing Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
- 7.1.2. Market Attractiveness Index By Testing Type
7.2. Carrier Testing*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Prenatal and Newborn Testing
7.4. Preimplantation Testing
7.5. Predictive and presymptomatic testing
7.6. Forensic testing
7.7. Diagnostic Testing
7.8. Others

8. Genetic Testing Market, By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Cancer Diagnosis*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Genetic Disease Diagnosis
8.4. Cardiovascular Disease Diagnosis
8.5. Others

9. Genetic Testing Market, By Regional Market Analysis and Growth Opportunities

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.7.1. U.S.
  - 9.2.7.2. Canada
  - 9.2.7.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.7.1. Germany
  - 9.3.7.2. U.K.
  - 9.3.7.3. France
  - 9.3.7.4. Spain
  - 9.3.7.5. Italy
  - 9.3.7.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.7.1. Brazil
  - 9.4.7.2. Argentina
  - 9.4.7.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.7.1. China
  - 9.5.7.2. India
  - 9.5.7.3. Japan
  - 9.5.7.4. South Korea
  - 9.5.7.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Testing Type
- 9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape and Market Positioning

10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking

11. Company Profiles

11.1.1. Abbott Laboratories*
11.1.2. Company Overview
11.1.3. Product Portfolio
- 11.1.3.1. Product Description
- 11.1.3.2. Product Key Performance Indicators (KPIs)
- 11.1.3.3. Historic and Forecasted Product Sales
- 11.1.3.4. Product Sales Volume
11.1.4. Financial Overview
- 11.1.4.1. Company Revenue
- 11.1.4.2. Geographical Revenue Shares
- 11.1.4.3. Revenue Forecasts
11.1.5. Key Developments
- 11.1.5.1. Mergers & Acquisitions
- 11.1.5.2. Key Product Development Activities
- 11.1.5.3. Regulatory Approvals, etc.
11.1.6. SWOT Analysis